Monoclonal antibodies for medical oncology: A few critical perspectives

Clinical and Translational Oncology

Volumn 13, Issue 2, 2011, Pages 84-87

  Belda Iniesta, Cristóbal ^a,b   Ibáñez De Cáceres, Inmaculada ^a   De Castro, Javier ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hospital de Madrid CIOCC   (Spain)

Author keywords

Cancer; Clinical trial; Monoclonal antibody

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CATUMAXOMAB; CD3 ANTIGEN; CETUXIMAB; CISPLATIN; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FC RECEPTOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MITOMYCIN; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PANITUMUMAB; PEMETREXED; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRASTUZUMAB; VASCULOTROPIN A; ANTINEOPLASTIC AGENT;

ASCITES TUMOR; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; OSTEOPOROSIS; OVARY CANCER; OVERALL SURVIVAL; PARACENTESIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; STOMACH CANCER; TREATMENT INDICATION; EVALUATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 79957976589     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0623-z     Document Type: Review

References (12)

1. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Eng J Med 354:809-820 (Pubitemid 43290919)
2. Cortés J, Saura C, Bellet M et al (2011) HER2 and hormone receptor-positive breast cancer-blocking the right target. Nat Rev Clin Oncol (in press)
3. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
4. Wagner AD, Grothe W, Behl S et al (2005) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev CD004064
5. Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004 (Pubitemid 34413593)
6. Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefi t from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2627
7. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
8. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
9. Burges A, Wimberger P, Kümper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13:3899-3905 (Pubitemid 47037597)
10. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209-2221
11. Keating GM (2010) Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 70:1059-1078
12. Neville-Webbe HL, Coleman RE (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46:1211-1222